弥漫性大 B 细胞淋巴瘤中复发富集患者系列中探索的突变动态和免疫逃逸。
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.
机构信息
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Norwegian Cancer Genomics Consortium, Oslo, Norway.
出版信息
Blood Adv. 2020 May 12;4(9):1859-1866. doi: 10.1182/bloodadvances.2019001325.
Abstract
Diagnostic and relapse diffuse large B-cell lymphoma (DLBCL) biopsies reveal increased mutational burden/loss of heterozygosity in . Serially sampled tumor biopsies provide insight into therapeutic targets and evolutionary divergence in relapsed/refractory DLBCL.
摘要
诊断和复发弥漫性大 B 细胞淋巴瘤（DLBCL）活检显示. 突变负担增加/杂合性丢失。连续取样的肿瘤活检为复发/难治性 DLBCL 的治疗靶点和进化分歧提供了深入了解。
相似文献
1
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.弥漫性大 B 细胞淋巴瘤中复发富集患者系列中探索的突变动态和免疫逃逸。
Blood Adv. 2020 May 12;4(9):1859-1866. doi: 10.1182/bloodadvances.2019001325.
2
Tumor evolution analysis uncovered immune-escape related mutations in relapse of diffuse large B-cell lymphoma.肿瘤进化分析揭示了弥漫性大B细胞淋巴瘤复发中与免疫逃逸相关的突变。
Leukemia. 2024 Oct;38(10):2276-2280. doi: 10.1038/s41375-024-02349-w. Epub 2024 Jul 30.
3
Genomic and transcriptomic characterization reveals B-cell hyperactivation and immune evasion in hepatitis B virus-associated diffuse large B-cell lymphoma.基因组和转录组特征揭示了乙型肝炎病毒相关弥漫性大B细胞淋巴瘤中的B细胞过度激活和免疫逃逸。
Clin Transl Med. 2023 Jun;13(6):e1293. doi: 10.1002/ctm2.1293.
4
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.基于分子取向的复发难治性弥漫性大B细胞淋巴瘤患者创新疗法：LNH-EP1研究结果
Am J Hematol. 2021 Oct 1;96(10):E376-E379. doi: 10.1002/ajh.26280. Epub 2021 Jul 10.
5
Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.弥漫性大 B 细胞淋巴瘤中体细胞突变的预后和治疗价值：系统评价。
Crit Rev Oncol Hematol. 2021 Sep;165:103430. doi: 10.1016/j.critrevonc.2021.103430. Epub 2021 Jul 30.
6
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.NOTCH通路在与丙型肝炎病毒感染相关的弥漫性大B细胞淋巴瘤中经常发生突变。
Haematologica. 2015 Feb;100(2):246-52. doi: 10.3324/haematol.2014.116855. Epub 2014 Nov 7.
7
lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p.长链非编码 RNA SNHG14 通过隔离 miR-152-3p 促进弥漫性大 B 细胞淋巴瘤的发生和免疫逃逸。
Leuk Lymphoma. 2021 Jul;62(7):1574-1584. doi: 10.1080/10428194.2021.1876866. Epub 2021 Mar 8.
8
CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma.CD2-阴性淋巴瘤相关 T 细胞：弥漫性大 B 细胞淋巴瘤免疫逃逸的潜在机制。
Virchows Arch. 2022 Oct;481(4):659-663. doi: 10.1007/s00428-022-03348-x. Epub 2022 May 27.
9
Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.基因组亚型可能预测弥漫性大B细胞淋巴瘤中枢神经系统复发的风险。
Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236.
10
MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中 MYD88 的表达和 L265P 突变。
Hum Pathol. 2013 Jul;44(7):1375-81. doi: 10.1016/j.humpath.2012.10.026. Epub 2013 Feb 4.
引用本文的文献
1
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.KLHL6 缺失促进 B 细胞淋巴瘤中癌基因受体信号转导。
Blood Cancer Discov. 2024 Sep 3;5(5):331-352. doi: 10.1158/2643-3230.BCD-23-0182.
2
Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphoma.预后突变特征可作为弥漫性大 B 细胞淋巴瘤患者的潜在预后预测指标。
Sci Rep. 2024 Mar 14;14(1):6161. doi: 10.1038/s41598-024-56583-4.
3
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.基因组复杂性与弥漫性大 B 细胞淋巴瘤中的表观遗传调节剂突变和不良预后相关。
Oncoimmunology. 2021 Jul 20;10(1):1928365. doi: 10.1080/2162402X.2021.1928365. eCollection 2021.
4
The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.免疫监测基因在诊断和难治/复发弥漫性大 B 细胞淋巴瘤中的突变特征。
BMC Cancer. 2021 Jul 18;21(1):829. doi: 10.1186/s12885-021-08556-3.
5
Treatment resistance in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的治疗抵抗。
Leukemia. 2021 Aug;35(8):2151-2165. doi: 10.1038/s41375-021-01285-3. Epub 2021 May 20.
6
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.复发/难治性弥漫性大B细胞淋巴瘤的突变谱与克隆进化
Front Oncol. 2021 Mar 11;11:628807. doi: 10.3389/fonc.2021.628807. eCollection 2021.
本文引用的文献
1
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.侵袭性 B 细胞非霍奇金淋巴瘤患者在强化一线治疗失败后的结局。
Cancer. 2020 Jan 15;126(2):293-303. doi: 10.1002/cncr.32526. Epub 2019 Sep 30.
2
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.使用肿瘤标志物连续动态分析进行个体化预后预测。
Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.
3
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.MHC 缺陷的分子和遗传特征鉴定 EZH2 作为增强免疫识别的治疗靶点。
Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.
4
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
5
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
6
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.复发性弥漫性大B细胞淋巴瘤中的突变进化
Cancers (Basel). 2018 Nov 20;10(11):459. doi: 10.3390/cancers10110459.
7
Open Targets Platform: new developments and updates two years on.开放靶点平台：两年的新发展和更新。
Nucleic Acids Res. 2019 Jan 8;47(D1):D1056-D1065. doi: 10.1093/nar/gky1133.
8
CADD: predicting the deleteriousness of variants throughout the human genome.CADD：预测整个人类基因组中变异的有害性。
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894. doi: 10.1093/nar/gky1016.
9
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.循环肿瘤 DNA 测量作为弥漫性大 B 细胞淋巴瘤的早期预后预测指标。
J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.
10
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.弥漫性大 B 细胞淋巴瘤的分子亚型与不同的发病机制和预后相关。
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
Zotero 插件